RxDoctor Payments DataLook up a doctor →

Oliver Abela, MD

Hospitalist · Fort Myers, FLNPI 1659690337

Payments from drug & device makers

$193,494in general payments, 2019–2025

Across 790 payments — averaging $244.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procyrion, Inc.$125K
  • Shockwave Medical, Inc$17K
  • Biotronik Inc.$9K
  • Inari Medical, Inc.$9K
  • AstraZeneca$7K
  • Abiomed$6K
  • plus $20K from 47 others
$180in research payments, 2019–2025

Across 3 payments — averaging $60.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$180

What the payments were for

  • Consulting fees$17,50023%
  • Speaking & faculty fees$19,60025%
  • Travel & lodging$9,59912%
  • Food & beverage$30,17439%
  • Education$1520%
  • Entertainment$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$193,494 in reported general payments places this provider in the 95th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$181,217
Medicare patients
338
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis14$316,669
EliquisApixaban149$140,407
FarxigaDapagliflozin Propanediol61$73,892
EntrestoSacubitril/Valsartan44$52,421
Repatha SureclickEvolocumab29$33,849
Atorvastatin Calcium217$2,225
Valsartan59$1,957
Ranolazine ErRanolazine16$1,883
ClopidogrelClopidogrel Bisulfate119$1,228
Metoprolol Succinate96$1,197
Rosuvastatin Calcium98$1,076
Carvedilol83$742
Losartan Potassium77$576
Potassium Chloride18$527
Flecainide Acetate13$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$275$457,076163 claims
AstraZenecaFarxiga$6,996$73,89261 claims
NovartisEntresto$597$52,42144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →